We conducted a study to test the hypothesis that the measles-mumps-rubella (MMR) vaccine can either prevent further recurrences of recurrent respiratory papillomatosis (RRP) or prolong its remission. Our study population was made up of 26 children with RRP. All patients underwent surgical excision of their lesions. After the lesions were removed, half of these patients were prospectively randomized to receive a topical coating of the MMR vaccine on the site of their excised lesion (intervention group); the other half were treated with excision alone (control group). The patients in the intervention group experienced a longer period of recurrence-free remission than did those in the control group (median: 160 and 133 days, respectively), but the difference was not statistically significant. Therefore, it appears that topical MMR vaccine as an adjunct to routine surgical management may not be beneficial in preventing or slowing the return of RRP. However, we believe that further studies with larger patient populations are warranted.
Introduction
Recurrent respiratory papillomatosis (RRP) is a chronic disease of the larynx. Many therapies have been tried, but there is no known cure and it remains difficult to treat. Although RRP is a generally benign condition, if left untreated it could spread throughout the respiratory tract and become fatal.
It has been reported that when combined with the surgical removal of papillomas, the injection of either the mumps vaccine 1 or the measles-mumps-rubella (MMR) vaccine 2 has a positive influence on remission in children with RRP. However, neither of these findings has been reproduced, and the mechanisms of these purported effects are unclear. We conducted a study to test the hypothesis that a topical coating of the MMR vaccine can prevent or prolong the remission of RRP.
Patients and methods
From January through December 2010, we enrolled 26 children, aged 1 to 16 years, with RRP into our study. They were prospectively randomized into two groups of 13 patients each. There was no statistically significant difference in age between the two groups. One group received a topical coating of MMR vaccine (5 ml) on the site of their excised lesions following surgery (intervention group), while the other group was treated with surgical excision alone (control group).
Excision was carried out by quickly debulking the neoplasm with a microdebrider via laryngeal endoscopy. For delivery of the MMR vaccine, a cotton ball was saturated with the vaccine, placed on the lesion site after the excision, and kept in place for 10 minutes.
Because most of our patients lived far from Shanghai in other provinces, very few were able to return to us on a regular basis for follow-up. In fact, they were not willing to return to Shanghai at all unless they were Volume 91, Number 4 www.entjournal.com  175
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resulTs of a preliminary randomized, conTrolled Trial experiencing serious dyspnea. Instead, we arranged for them to undergo their examinations at local hospitals. Patients older than 6 years were evaluated by rigid laryngoscopy, while younger patients were assessed by lateral neck x-rays. We conducted our monthly follow-up evaluations by telephone. During these telephone calls, patients informed us of the results of their follow-up visits, and they were asked about any worsening hoarseness or dyspnea. Those who complained of these symptoms were advised to return to our hospital for an immediate examination. If this was not possible, they were asked to return for a follow-up examination every 2 months, but again, this was rarely possible.
Results were quantified by calculating the number of symptom-free days in all patients. For those who experienced a recurrence, we calculated the number of days between the initial surgery and the second surgery to treat the recurrence. For those patients who did not experience a recurrence, we calculated the number of days between their surgery and March 31, 2011.
Kaplan-Meier estimates were used to analyze outcomes. In addition, a one-way analysis of variance (ANOVA) was used to compare the means of symptom scores before and after surgery to see if symptoms had been alleviated by the MMR vaccine.
Our study protocol was approved by our hospital's ethics committee, and all patients provided written informed consent prior to treatment.
Results
RRP recurred in 8 patients in the intervention group and 7 patients in the control group. The median duration of remission was 160 and 133 days, respectively; this difference was not statistically significant.
Most patients required only one or two surgeries during the year, but some required many more. In fact, 7 patients (3 in the intervention group and 4 in the control group) required between 4 and 11 revision surgeries during the year. Four patients (2 intervention, 2 control) underwent their second surgery within 1 month of their first, and 3 patients (2 intervention, 1 control) required revision surgery every month.
Analysis of symptom scores revealed that most patients had mild symptoms, but that there was no significant difference between the two groups in symptom scores.
Discussion
Based on our findings, it appears that topical MMR vaccine as an adjunct to routine surgical management may not be beneficial in preventing or slowing the return of RRP. We believe that there are two factors that might account for our findings. The first is our sample size, which might not have been large enough to detect small but significant differences. The second is the way we administered the vaccine. Pashley reported that injection of the mumps vaccine may induce remission in RRP. 1 In our study, we chose to apply a coat of the MMR vaccine on the lesion site, which we believe is safer than injection. However, that might have resulted in less absorption of the vaccine.
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